ClinicalTrials.gov Noncompliance Remains An FDA Concern
Executive Summary
The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12
You may also be interested in...
FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings
FDA believes it has the authority to independently post clinical study information on ClinicalTrials.gov, but does not plan to create a systematic process for increasing the number of industry-sponsored trials listed on the site
ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman
Industry may need several years to come into complete compliance with ClinicalTrials.gov, the Pharmaceutical Research & Manufacturers of America indicated in a letter to Rep. Henry Waxman (D-Calif.)
FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings
FDA believes it has the authority to independently post clinical study information on ClinicalTrials.gov, but does not plan to create a systematic process for increasing the number of industry-sponsored trials listed on the site